Stockreport

Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted [Seeking Alpha]

Monopar Therapeutics Inc.  (MNPR) 
PDF ALXN-1840, acquired from AstraZeneca, targets Wilson disease with an NDA filing anticipated in early 2026, but approval remains uncertain. MNPR's radiopharmaceutical [Read more]